TX-HYOSUNG-AMERICA
12.7.2022 13:02:07 CEST | Business Wire | Press release
Hyosung America announced today that DigitalMint , the premier cash-to-cryptocurrency provider, has signed a partnership agreement with Hyosung America to add DigitalMint services to its soon-to-be-launched API-based app store.
As the leading Bitcoin point-of-sale provider in the nation, DigitalMint allows customers to buy cryptocurrency instantly at ATM and teller locations across the United States. They've also developed a software API integration that enables retailers to sell Bitcoin through their current point-of-sale system. DigitalMint, founded in 2014, can be found in financial service centers, convenience stores, grocery chains, gas stations, and retail locations across the country.
“We’re thrilled to be the first product on the upcoming Hyosung app store,” said Don Wyper, Chief Operating Officer of DigitalMint, “We're looking forward to working with Hyosung America to make cryptocurrency services easily and safely accessible to their 175,000 deployed ATMs in the United States and beyond.”
“Our nationwide distribution scale and relationships with top ATM value-added resellers and independent operators provides DigitalMint with unprecedented scale for its growing customer base,” said Hee-Eun Ahn, CEO for Hyosung America.
“We are excited to include DigitalMint into our soon-to-be-launched app store. With the app store, any ATM operator using our retail software platform can subscribe and download apps such as DigitalMint, to enable their ATMs to do more – driving new revenue streams for the operators and the retailers with whom they partner,” said Brad Nolan, CMO for Hyosung America. “This is as easy as an app download in our new Series X Metakiosks, and in conjunction with our newly launched X10 Cash-In-Sidecar, any Hyosung cash dispenser can instantly transform into a full function device and tap into a whole new universe of transactions including bill pay, check cashing, cash deposits, POS purchase and of course cryptocurrency purchase.”
The company plans to launch their DigitalMint partnership and new products in a live webinar on Tuesday, July 12 at 2 p.m. CT. Registration for that webinar, which will remain on the site following the live stream, can be found here: https://marketscale.com/live/hyosung-summer-2022-retail-product-launch/ .
About Hyosung America
Hyosung America, the world’s leading cash management and payments platform service provider, is the North American subsidiary of South Korea-based Hyosung, Inc. Since entering the North American market in 1998, Hyosung has grown from the largest provider of ATMs in the United States, to offering best-in-class, innovative and transformative technology solutions across the cash management and payments spectrum. Hyosung America is headquartered in Irving, Texas, and provides research and development support in its Global Software Center in Dayton, Ohio.
About DigitalMint
DigitalMint is the premier cash-to-cryptocurrency provider, enabling consumers to buy cryptocurrency safety and securely through our nationwide network of ATMs and tellers. Our mission is to empower consumers to take control of their financial future by utilizing digital currencies as a tool for financial access. Founded in 2014, DigitalMint is an industry leader in cryptocurrency compliance standards, providing safe and secure access to cryptocurrencies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005368/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom